Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine for Behavioral Frontotemporal Dementia
NCT04937452Phase 2Completed
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rotigotine in frontotemporal dementia (FTD) (3 arms), sponsored by Fondazione Santa Lucia IRCCS. Primary endpoint: Frontal Assessment Battery at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
rotigotine
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04937452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937452.